GlassScriptPhysician profile
Jennifer A Monaco
NPI 1306003850
$12,522.05
in general payments reported to CMS, 2019-2025
41 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,492 · 2020: $77.69 · 2021: $118 · 2022: $3,649 · 2023: $3,547 · 2024: $1,438 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,635 · Travel and Lodging: $2,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,634.95 |
| Travel and Lodging | $2,550.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Anika Therapeutics, INC. | $1,824.72 | 2022-2023 | Drawtight, X-Twist, Tactoset |
| Kairos Surgical INC | $1,245.08 | 2022 | |
| Wright Medical Technology, INC. | $1,150.39 | 2019 | |
| Paragon 28, INC. | $1,149.36 | 2023-2024 | Portfolio, Apex 3d |
| Zimmer Biomet Holdings, INC. | $1,068.65 | 2019 | |
| Arthrex, INC. | $1,034.96 | 2023 | |
| Cgg Medical INC | $687.80 | 2023 | |
| Treace Medical Concepts, INC. | $627.18 | 2022 | |
| Orthofix Medical, INC. | $425.89 | 2022-2025 | Truelok, Truelok Evo |
| Integra Lifesciences Corporation | $419.69 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Smith+Nephew, INC. | $418.81 | 2022-2025 | Collagenase Santyl, Grafix, Renasys Go V2 Home |
| Polynovo North America LLC | $337.24 | 2024-2025 | Novosorb Btm |
| Access Pro Medical, LLC | $208.28 | 2025 | Matriderm |
| Endo Pharmaceuticals INC. | $194.63 | 2019-2022 | |
| Axogen | $169.25 | 2023 | Avance Nerve Graft |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $158.68 | 2023-2025 | Nuzyra |
| Medtronic, INC. | $156.17 | 2024 | Closurefast, Venaseal |
| Arteriocyte Medical Systems, INC. | $141.81 | 2022-2025 | Magellan |
| Acera Surgical, INC. | $118.52 | 2024 | Restrata Wound Matrix |
| Depuy Synthes Sales INC. | $112.33 | 2019-2020 | |
| Arthrosurface Incorporated | $90.75 | 2019 | |
| Amgen INC. | $87.58 | 2024-2025 | Krystexxa |
| Convatec INC. | $77.59 | 2023 | |
| Solventum Corporation | $77.05 | 2024-2025 | Prevena, Activ.A.C., V.A.C. Veraflo |
| Mimedx Group, INC. | $76.08 | 2024 | |
| Ibsa Pharma INC. | $67.77 | 2023-2025 | Tirosint, Tirosint, Licart |
| Lifenet Health | $59.63 | 2024 | Theragenesis Wound Matrix |
| Baxter Healthcare | $46.14 | 2019 | |
| Bioventus LLC | $43.06 | 2020-2023 | Stimrouter Implantable Kit |
| Biowound Solutions, INC. | $41.56 | 2025 | Bio-Connekt |
| Vertex Pharmaceuticals Incorporated | $29.86 | 2024 | |
| Djo, LLC | $24.78 | 2019 | |
| Kci USA, INC. | $23.98 | 2021 | |
| Kerecis Limited | $23.83 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Cashflow Solutions, LLC | $23.38 | 2023 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
| Averitas Pharma INC. | $15.46 | 2023 | Qutenza |
| Wishbone Medical INC. | $13.43 | 2023 | |
| Hartmann USA, INC. | $13.25 | 2024 | Zetuvit Plus 10x10 P10 |
| Hydrofera LLC | $13.25 | 2024 | Cutimed Sorbion |
| Horizon Therapeutics Plc | $12.81 | 2023 | Krystexxa |
| Ultragenyx Pharmaceutical INC. | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Monaco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.